Stryker (NYSE:SYK) Issues FY 2026 Earnings Guidance

Stryker (NYSE:SYK) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 14.900-15.100 for the period, compared to the consensus EPS estimate of 14.950. The company issued revenue guidance of -.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a report on Tuesday, January 6th. Piper Sandler reissued an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday. Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday. Finally, Truist Financial decreased their price objective on Stryker from $395.00 to $380.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $401.43.

Stryker Trading Down 6.3%

Shares of SYK stock traded down $19.70 during mid-day trading on Friday, hitting $295.43. 4,518,113 shares of the company’s stock were exchanged, compared to its average volume of 1,836,681. Stryker has a fifty-two week low of $294.55 and a fifty-two week high of $404.87. The stock has a 50-day simple moving average of $345.67 and a two-hundred day simple moving average of $356.95. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The stock has a market cap of $113.15 billion, a price-to-earnings ratio of 35.17, a PEG ratio of 1.84 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.74% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business earned $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker will post 14.91 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Investors of record on Tuesday, March 31st were issued a $0.88 dividend. The ex-dividend date was Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.60% of the company’s stock.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY?2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer?term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near?term upside expectations and add selling pressure. Article Title

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SYK. Wellington Management Group LLP raised its position in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares during the period. Corient Private Wealth LLC raised its position in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the period. Credit Agricole S A purchased a new position in Stryker in the third quarter valued at about $194,045,000. Dimensional Fund Advisors LP raised its position in Stryker by 35.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,260,651 shares of the medical technology company’s stock valued at $443,113,000 after purchasing an additional 327,490 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Stryker by 293.6% during the fourth quarter. Renaissance Technologies LLC now owns 406,160 shares of the medical technology company’s stock worth $142,753,000 after acquiring an additional 302,960 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.